Biotech Values

[investorgold2002]

"Copaxone® is the leading multiple sclerosis therapy in the U.S. and globally with an improved global market share of 31%. Global in-market sales reached $907 million in the first quarter of 2011, an increase of 14%. In the U.S., in-market sales increased 22% to $624 million, as a result of price increases as well as volume growth. In-market sales outside the U.S. were flat at $283 million with 6% unit growth. Unit growth in several European and Latin American markets, including the U.K., Italy, Spain, Brazil and Mexico, was offset by price decreases in Germany and other markets."